Quinoline-based fibroblast activation protein(FAP)inhibitor(FAPI)-based positron emission tomography(PET)imaging and radioligand therapy(RLT)are being investigated for use in a wide variety of diseases,and recent resu...Quinoline-based fibroblast activation protein(FAP)inhibitor(FAPI)-based positron emission tomography(PET)imaging and radioligand therapy(RLT)are being investigated for use in a wide variety of diseases,and recent results have been promising.This review summarizes the current status of FAPI radiopharmaceuticals in PET imaging of malignant tumors and benign conditions and compares their diagnostic efficacy with ^(18)F-fluorodeoxyglucose.In addition,we summarize the previously published FAP-targeted RLT data and discuss its current clinical use and future potential.Our qualitative summary can inform future research directions,medical guidelines,and optimal clinical decision-making.展开更多
目的:探讨^(68)Ga标记的成纤维细胞激活蛋白抑制剂(fibroblast activation protein inhibitor,FAPI)-04正电子发射断层显像/X线计算机体层成像(positron emission tomography and computed tomography,PET/CT)对初诊胰腺癌的诊断价值及...目的:探讨^(68)Ga标记的成纤维细胞激活蛋白抑制剂(fibroblast activation protein inhibitor,FAPI)-04正电子发射断层显像/X线计算机体层成像(positron emission tomography and computed tomography,PET/CT)对初诊胰腺癌的诊断价值及对肿瘤分期的影响。方法:回顾性收集2021年8月至2023年8月于重庆大学附属肿瘤医院就诊的134例因怀疑胰腺占位的患者临床及影像资料。分析^(68)Ga-FAPI-04 PET/CT对胰腺癌原发灶及转移灶的诊断价值;并与传统CT比较,分析^(68)Ga-FAPI-04 PET/CT对胰腺癌肿瘤分期的影响。结果:共计纳入134例患者,其中胰腺癌127例,良性病变7例。^(68)Ga-FAPI-04 PET/CT对胰腺癌原发灶、区域淋巴结及远处转移灶检出率分别为100%(127/127)、68.63%(35/51),95.35%(41/43)。胰腺癌中位最大标准化摄取值(standard uptake value maxium,SUVmax)为14.92,高于胰腺良性病变中位SUVmax(6.1)(Z=−2.921,P=0.003)。与传统CT比较,^(68)Ga-FAPI PET/CT检查后共有32.28%(41/127)胰腺癌患者TNM分期发生改变。3.94%(5/127)患者改变了治疗方案。结论:^(68)Ga-FAPI-04 PET/CT对胰腺癌原发灶诊断具有较高的敏感性,较传统CT可发现更多远处转移病灶,改善患者M分期,有助于全面评估全身肿瘤负荷、制定治疗计划。展开更多
目的研究Al^(18)F-1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA)-成纤维细胞激活蛋白抑制剂(FAPI)-04 PET/CT显像非肿瘤摄取的分布特征,并探讨其生物学意义。方法回顾性横断面研究。连续纳入2022年12月至2023年8月期间在江南大学附属医院接受...目的研究Al^(18)F-1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA)-成纤维细胞激活蛋白抑制剂(FAPI)-04 PET/CT显像非肿瘤摄取的分布特征,并探讨其生物学意义。方法回顾性横断面研究。连续纳入2022年12月至2023年8月期间在江南大学附属医院接受Al^(18)F-NOTA-FAPI-04 PET/CT检查的90例肿瘤或高度疑似肿瘤患者[男55例、女35例,年龄(63.3±9.7)岁]的PET/CT图像和临床资料。采用SUV max评估全身非肿瘤灶(正常器官和良性病变)摄取水平和分布特征,组间比较采用Mann-Whitney U检验。结果正常器官存在不同程度的生理性摄取特征,其中下颌下腺、胆道系统和子宫呈明显摄取(SUV max 5.0~9.0);腭扁桃体、甲状腺和胰腺呈中度摄取(SUV max 3.0~5.0);腮腺、左心室壁、肝、脾、肾、肌肉、前列腺呈轻度摄取(SUV max 1.6~3.0)。甲状腺炎组(7例)甲状腺摄取高于甲状腺功能正常组(17例)[4.95(2.61,9.20)和2.80(2.25,3.41);Z=-2.06,P=0.040],肝实质损伤组(7例)肝脏摄取高于无实质损伤组(49例)[3.11±0.88和1.88(1.34,3.22);Z=-1.97,P=0.049]。结论在Al^(18)F-NOTA-FAPI-04 PET/CT显像中,正常器官存在不同程度的生理性摄取特征。甲状腺炎、肝实质损伤等良性病变可能会影响摄取程度,需结合临床信息综合判断。展开更多
基金Key Scientific Research Program for Young Scholars in Fujian,Grant/Award Number:2021ZQNZD016Fujian Natural Science Foundation for Distinguished Young Scholars,Grant/Award Number:2022D005+3 种基金Medical and Health Guidance Projects of Xiamen,Grant/Award Numbers:3502Z20209269,3502Z20224ZD1001National Natural Science Foundation of China,Grant/Award Numbers:82071961,82102094Fujian Natural Science Foundation for Youth Innovation,Grant/Award Number:2022J05314Fujian Research and Training Grants for Young and Middle-Aged Leaders in Healthcare。
文摘Quinoline-based fibroblast activation protein(FAP)inhibitor(FAPI)-based positron emission tomography(PET)imaging and radioligand therapy(RLT)are being investigated for use in a wide variety of diseases,and recent results have been promising.This review summarizes the current status of FAPI radiopharmaceuticals in PET imaging of malignant tumors and benign conditions and compares their diagnostic efficacy with ^(18)F-fluorodeoxyglucose.In addition,we summarize the previously published FAP-targeted RLT data and discuss its current clinical use and future potential.Our qualitative summary can inform future research directions,medical guidelines,and optimal clinical decision-making.
文摘目的研究Al^(18)F-1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA)-成纤维细胞激活蛋白抑制剂(FAPI)-04 PET/CT显像非肿瘤摄取的分布特征,并探讨其生物学意义。方法回顾性横断面研究。连续纳入2022年12月至2023年8月期间在江南大学附属医院接受Al^(18)F-NOTA-FAPI-04 PET/CT检查的90例肿瘤或高度疑似肿瘤患者[男55例、女35例,年龄(63.3±9.7)岁]的PET/CT图像和临床资料。采用SUV max评估全身非肿瘤灶(正常器官和良性病变)摄取水平和分布特征,组间比较采用Mann-Whitney U检验。结果正常器官存在不同程度的生理性摄取特征,其中下颌下腺、胆道系统和子宫呈明显摄取(SUV max 5.0~9.0);腭扁桃体、甲状腺和胰腺呈中度摄取(SUV max 3.0~5.0);腮腺、左心室壁、肝、脾、肾、肌肉、前列腺呈轻度摄取(SUV max 1.6~3.0)。甲状腺炎组(7例)甲状腺摄取高于甲状腺功能正常组(17例)[4.95(2.61,9.20)和2.80(2.25,3.41);Z=-2.06,P=0.040],肝实质损伤组(7例)肝脏摄取高于无实质损伤组(49例)[3.11±0.88和1.88(1.34,3.22);Z=-1.97,P=0.049]。结论在Al^(18)F-NOTA-FAPI-04 PET/CT显像中,正常器官存在不同程度的生理性摄取特征。甲状腺炎、肝实质损伤等良性病变可能会影响摄取程度,需结合临床信息综合判断。
文摘目的探讨^(68)Ga-FAPI PET/CT对初诊食管癌患者原发病灶及转移病灶的检出能力,并与^(18)F-FDG PET/CT进行比较。方法回顾分析厦门大学附属第一医院2019-12-01-2022-12-30行^(18)F-FDG和^(68)Ga-FAPI PET/CT检查的32例食管癌患者,其中男26例,女6例,年龄43~85岁,平均年龄(62.16±10.11)岁。采用配对t检验或Wilcoxon符号秩检验比较^(68)Ga-FAPI与^(18)F-FDG在病灶中的最大标准摄取值(SUV_(max))及2种显像检出的病变数量,采用Pearson相关性分析确定显像剂摄取值高低与原发病灶大小之间的关系,采用方差分析或Kruskal-Wallis秩和检验比较3种不同病理分化类型病灶间SUV_(max)的差异。结果32例初诊食管癌患者中有30例鳞状细胞癌与2例腺癌。在食管癌原发病灶中,^(68)Ga-FAPI的SUV_(max)比^(18)F-FDG更高(17.43±5.74 vs 12.94±4.67,t=-4.128,P<0.001)。^(68)Ga-FAPI的SUV_(max)与原发病灶的纵向直径不相关(r=0.111,P=0.545),但^(18)F-FDG的SUV_(max)与其相关(r=0.368,P=0.038)。在两者共检测出的130个可疑淋巴结转移病灶中,^(68)Ga-FAPI的SUV_(max)较^(18)F-FDG更高[8.72(5.30,12.68)vs 5.88(3.78,13.50),Z=-6.150,P<0.001];且在同一患者中,^(68)Ga-FAPI能检测出更多可疑的淋巴结转移病灶[3.0(1.0,5.0)vs 3.0(2.0,5.0),Z=-2.254,P=0.024]。在两者共同检测出的21个远处转移病灶中,^(68)Ga-FAPI的SUV_(max)比^(18)F-FDG更高(12.11±4.42 vs 6.37±1.73,t=-6.263,P<0.001)。结论^(68)Ga-FAPI较^(18)F-FDG在食管癌原发和转移病灶中有更高的放射性摄取,在视觉分析中能发现更多的转移病灶,有利于初诊食管癌患者个体化治疗方式选择。
